RVL Pharmaceuticals plc CEO Brian Markison's 2021 pay falls 63% to $1.4M
RVL Pharmaceuticals plc reports 2021 executive compensation
By ExecPay News
Published: April 24, 2023
RVL Pharmaceuticals plc reported fiscal year 2021 executive compensation information on April 24, 2023.
In 2021, four executives at RVL Pharmaceuticals plc received on average a compensation package of $946K, a 51% decrease compared to previous year.
Average pay of disclosed executives at RVL Pharmaceuticals plc
Brian Markison, Chief Executive Officer, received $1.4M in total, which decreased by 63% compared to 2020. 54% of Markison's compensation, or $769K, was in option awards. Markison also received $665K in salary.
James Schaub, Chief Operating Officer, received a compensation package of $832K, which decreased by 38% compared to previous year. 50% of the compensation package, or $418K, was in salary.
Christopher Klein, General Counsel, earned $824K in 2021, a 37% decrease compared to previous year.
Tina deVries, Former EVP, Research & Development, received $693K in 2021, which decreases by 47% compared to 2020.
Related executives
You may also like
Source: SEC filing on April 24, 2023.